key: cord-0868476-bxuhz7wc
authors: Siow, Isabel; Lee, Keng Siang; Zhang, John J. Y.; Saffari, Seyed Ehsan; Ng, Adeline
title: Encephalitis as a neurological complication of COVID‐19: A systematic review and meta‐analysis of incidence, outcomes, and predictors
date: 2021-06-02
journal: Eur J Neurol
DOI: 10.1111/ene.14913
sha: 66d05cab2141a112136b6fd0e762a8ace40cf618
doc_id: 868476
cord_uid: bxuhz7wc

BACKGROUND AND PURPOSE: Although COVID‐19 predominantly affects the respiratory system, recent studies have reported the occurrence of neurological disorders such as stroke in relation to COVID‐19 infection. Encephalitis is an inflammatory condition of the brain that has been described as a severe neurological complication of COVID‐19. Despite a growing number of reported cases, encephalitis related to COVID‐19 infection has not been adequately characterised. To address this gap, this systematic review and meta‐analysis aims to describe the incidence, clinical course, and outcomes of patients who suffer from encephalitis as a complication of COVID‐19. METHODS: All studies published between 1 November 2019 and 24 October 2020 that reported on patients who developed encephalitis as a complication of COVID‐19 were included. Only cases with radiological and/or biochemical evidence of encephalitis were included. RESULTS: In this study, 610 studies were screened and 23 studies reporting findings from 129,008 patients, including 138 with encephalitis, were included. The average time from diagnosis of COVID‐19 to onset of encephalitis was 14.5 days (range = 10.8–18.2 days). The average incidence of encephalitis as a complication of COVID‐19 was 0.215% (95% confidence interval [CI] = 0.056%–0.441%). The average mortality rate of encephalitis in COVID‐19 patients was 13.4% (95% CI = 3.8%–25.9%). These patients also had deranged clinical parameters, including raised serum inflammatory markers and cerebrospinal fluid pleocytosis. CONCLUSIONS: Although encephalitis is an uncommon complication of COVID‐19, when present, it results in significant morbidity and mortality. Severely ill COVID‐19 patients are at higher risk of suffering from encephalitis as a complication of the infection.

, Guillain-Barré syndrome [4] and myelitis [5] are still not adequately explored.

There have been increasing reports of the development of encephalitis in severely ill COVID-19 patients [6] [7] [8] . These patients fare poorly, with significant morbidity and mortality rates [6, 9] .

The association of encephalitis with severe patient outcomes suggests that systematic studies are required to determine the risk factors predisposing to its development. Currently, systematic reviews that consolidate findings on encephalitis as a complication of COVID-19 are scarce, providing limited information on this condition [10] [11] [12] [13] . To address this important gap in the literature, a systematic review was conducted to more comprehensively evaluate the epidemiology, clinical course, risk factors, and outcomes of patients who suffer from encephalitis as a complication of COVID-19.

Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines [14] . A search string was developed to identify original research studies reporting clinical features and treatment outcomes of patients with encephalitis as a complication of COVID-19 (Table S1 ). Encephalitis was defined as an inflammation of the brain [15] . For this analysis, studies reporting on any type of encephalitis were included, such as autoimmune encephalitis, acute All original studies reporting the clinical characteristics (symptoms and signs, laboratory investigations, and radiological findings) and treatment outcomes of COVID-19 patients with encephalitis complications were included in our systematic review. Case reports and studies of small sample sizes (<3) were excluded per recommendations in accordance with methodologies of previously published meta-analyses [2, 16] . Other exclusion criteria included non-English articles, non-original research papers, laboratory-based and epidemiological studies with no clinical characteristics reported, and nonhuman research subjects (Table S2 ). The PRISMA chart is detailed in Figure 1 .

The quality of included studies was assessed using the Joanna Briggs Institute (JBI) checklist for prevalence studies and the JBI checklist for case series [17] . These tools rated the quality of selection, measurement, and comparability for all studies and gave a score for crosssectional studies and case series. Two researchers assessed the quality of all included studies and discussed discrepancies until consensus was reached. Data were extracted on the following variables: study details, sample size of study, method of diagnosis, age, gender, coexisting medical conditions, clinical symptoms, laboratory investigations, time from COVID-19 infection to onset of encephalitis, treatment details, and patient outcomes. The outcome measure was mortality in hospital.

Random effects meta-analyses were performed on variables and end points due to observed estimates and sampling variability across studies. Pooled proportions were computed with the inverse variance method using the variance-stabilising Freeman-Tukey double arcsine transformation [18] . Confidence intervals (CIs) for individual studies were calculated using the Clopper-Pearson interval method. The I 2 statistics was used to present between-study heterogeneity, where I 2 of 30% or less, between 30% and 50%, between 50% and 75%, and 75% or greater was considered to indicate low, moderate, substantial, and considerable heterogeneity, respectively [19] . Probability values for the I 2 statistics were computed by chi-squared distribution of Cochran Q test. Missing values for mean were imputed using median.

Computing, Vienna, Austria; https://www.R-proje ct.org/) [20] . The significance level was set at p < 0.05, and 95% CIs were reported.

The search strategy yielded 610 unique publications after removal of duplicates. After screening of titles and abstracts, 168 publications were reviewed in full text. A total of 23 original studies [3, [6] [7] [8] [9] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] were eventually included in our systematic review with a combined population of 129,008 patients, including 138 who developed encephalitis [ Table 1 ].

Of the 23 studies, five studies each originated from the United States and Italy. Three studies each originated from Spain and France, two studies each originated from Singapore and the United Kingdom, and one study each originated from Belgium, Pakistan, and Turkey (Table 1) . Sixteen studies were cross-sectional in nature (69.6%), and seven (30.4%) were case series. Of the 16 crosssectional studies, four studies attained a full score of 8 on the JBI checklist for cross-sectional studies, eight studies attained a score of 7, and four studies attained a score of 6 (Table S3) . Of the seven case series, four studies attained a full score of 10 on the JBI checklist for case series and three studies attained a score of 9 (Table S4 ).

The two broad categories of encephalitis as a complication of COVID-19 were autoimmune encephalitis and infectious encephalitis.

Fourteen studies reported on the incidence of encephalitis as a complication of COVID-19. Combining results, the pooled incidence of encephalitis as a complication of COVID-19 was 0.215% (95% CI = 0.056%-0.441%). Notably, 10 of the 14 studies reported incidence of less than 1% ( Figure 2 ). However, among severely ill patients with COVID-19, the pooled incidence of encephalitis as a complication of COVID-19 was higher at 6.7% (95% CI = 4.3%-9.4%; Figure S1 ). Ten Table 2 ).

Twelve studies reported on the severity of COVID-19 illness in patients who subsequently suffered from the complication of encephalitis, whether severe of mild. Severe illness was defined as patients who required intensive care unit (ICU) or high-dependence unit (HDU) care. Mild illness included patients who were managed in the general ward with mild or no respiratory symptoms during their stay.

Most patients had severe COVID-19 illness prior to developing the complication of encephalitis, amounting to 83.8% (95% CI = 62.0%-98.6%; Figure S2 ). Table 1) . Most of these patients had at least one comorbidity, amounting to 71.7%. The most common comorbidities were hypertension (45.5% of patients), hyperlipidaemia (24.0%), and diabetes mellitus (16.0%). Less commonly encountered comorbidities included chronic kidney disease, chronic liver disease, and congestive cardiac failure (Table 3) .

Thirteen studies reported on the clinical symptoms of patients, such as COVID-19 symptoms and encephalitis symptoms. Of the eight studies that reported on COVID-19 symptoms, shortness of breath (84.6% of patients) and fever (63.6%) were the most common symptoms experienced by patients. Cough (60.0%) and fatigue (50.0%) were less common. Additionally, 23.8% of patients were asymptomatic, that is, did not experience any COVID-19 symptoms. Of the 11 studies that reported on symptoms of encephalitis, all reported that all the patients in the study experienced at least one symptom of encephalitis. Other less common symptoms that patients with encephalitis as a complication of COVID-19 suffered from were aphasia, ataxia, and myoclonus (Table 4) .

Clinical parameters of COVID-19 patients who suffered from encephalitis as a complication were also analysed. Six studies reported results of serum analyses. D-dimer levels were raised, with an average of 13.4 mg/L (range = 6.9-15.0 mg/L). Lactate dehydrogenase levels were raised, with an average of 358.7 U/L (range = reported on oligoclonal bands, three studies found that they were absent in eight patients, whereas one study reported its presence in one patient (Table 5) .

Thirteen studies reported on the mortality rate of patients who suffered from encephalitis as a complication of COVID-19. The pooled mortality rate of patients who suffered from encephalitis as a complication of COVID-19 was 13.4% (95% CI = 3.8%-25.9%; Figure 3 ).

A comprehensive evaluation of the epidemiology and clinical outcomes of patients who suffered from encephalitis as a complication of COVID-19 was performed. A key finding is that the incidence of encephalitis in COVID-19 patients is relatively low (<1%), but as, although uncommon, it can have severe consequences [6] .

Several risk factors for encephalitis as a complication of COVID-19 were elucidated. Demographic risk factors such as old age and underlying comorbidities may confer increased risk of complications from COVID-19 infection, including the development of encephalitis [9, 21, 32] . Additionally, patients who are severely ill with COVID-19 are at a much-increased risk of suffering from the complication of encephalitis [6, 8, 22] . The incidence of encephalitis as a complication of COVID-19 is less than 1% in the general population of COVID-19 patients, but rises greatly to 6.7% in those who are severely ill. The physiological reserves theory might explain this phenomenon. The elderly with multiple comorbidities, or those who are severely ill with COVID-19, are less able to compensate for physiological derangements, increasing vulnerability to severe complications such as encephalitis [40] . Common MRI brain findings seen in these cases include diffuse white matter hyperintensities and haemorrhagic lesions on fluidattenuated inversion recovery and T2 sequences [24, 25, 33, 35, 37] .

Other less common MRI findings include cerebral oedema and venous thrombosis [3, 9] . CT head findings were generally unremarkable [24] . Notably, some of these patients suffered from pre-existing chronic medical conditions such as diabetes mellitus and hypertension [24, 37] and it is possible that some degree of imaging findings such as subcortical white matter hyperintensities and microbleeds in the deep grey nuclei could have resulted from chronic conditions such as hypertension. However, there are also a few reports of patients with encephalitis as a complication of COVID-19 with normal brain imaging results [6] . This could be due to milder encephalitis or imaging conducted prematurely before brain changes developed.

Neuroimaging findings in patients with encephalitis as a complication of COVID-19 resemble those in the previous severe acute respiratory syndrome coronavirus 1 (SARS-CoV-1) and Middle East respiratory syndrome outbreaks, suggesting possible similarities in pathophysiology of central nervous system (CNS) involvement across these three coronaviruses [13] . Electroencephalography (EEG) in some patients showed patterns of general slowing [24] .

Although some patients developed seizures during their clinical course [32, 34] , sharp waves and epileptiform activity were uncommon findings [24, 33] .

Interestingly, there have been increasing reports of severe encephalitis subtypes occurring even among young COVID-19

patients, such as ADEM [41, 42] . ADEM is a postinfectious inflammatory demyelinating neurological condition that is more common in children than adults [43] . It is a serious form of encephalitis with Reference value < 6.5 pg/ml. much poorer outcomes compared to those in other subtypes of encephalitis, including poor functional recovery and a high mortality rate [43] . Worryingly, preliminary reports show that ADEM is not exclusive to COVID-19 patients with demographic risk factors, as young COVID-19 patients and those with no comorbidities also develop this complication [41, 42] . These patients also often develop new white matter lesions seen on contrast-enhancement MRI [44] .

Further surveillance is warranted to improve management of these lethal subtypes of encephalitis.

Efficacious management protocols for encephalitis in COVID-19 are still being studied. Modes of management that have yielded positive patient outcomes include corticosteroids [21] , intravenous immunoglobulin [30] , plasmapheresis [9] and monoclonal antibodies such as rituximab [45] . In a case series of five patients by Cao et al., administration of corticosteroids (1 g/ day intravenous methylprednisolone for 5-10 days) resulted in marked improvement of three patients, who showed dramatic improvement of neurologic status within 1 week and were subsequently discharged [21] . A combination of intravenous immunoglobulin and corticosteroids was successful in the treatment of COVID-19 patients with inflammatory CNS conditions such as encephalitis, where 11 of the 12 patients studied recovered [30] Plasmapheresis was also shown to be effective in a case series of six critically ill COVID-19 patients with encephalitis, where five of them recovered enough after commencement of plasmapheresis to be discharged from the ICU to a normal ward [9] . Rituximab was also effective in the treatment of an elderly gentleman with COVID-19 encephalitis, causing marked improvement in neuropsychiatric symptoms and mental status after administration [45] . However, the preliminary success of these treatment modalities needs to be considered cautiously, as no large-scale randomised control trials regarding their efficacy have been published to date.

More work needs to be carried out in this area to determine their leukocytes [46] . Lymphocytes, monocytes, and granulocytes all express the ACE-II receptor, making infection with SARS-CoV-2 possible. Once infected in blood vessels, these leukocytes cross the BBB, entering the CNS and taking the SARS-CoV-2 virus with them, where they can infect other cell types within the CNS to cause encephalitis [46] . However, it has been suggested that direct invasion of SARS-CoV-2 virus into the CNS may be less likely to be the main mechanism causing encephalitis in COVID-19 [12, 13] , as most patients with encephalitis in COVID-19 have had negative CSF polymerase chain reaction against SARS-CoV-2, and symptoms of direct CNS involvement such as anosmia and ageusia have been very uncommon [30, [32] [33] [34] .

Another proposed mechanism for the pathophysiology of en- [24, 28, 30] . Additionally, EEG results reveal diffuse patterns indicative of extensive inflammation [13] . Further studies reporting CSF and/or serum levels of such inflammatory cytokines may be useful for elucidating underlying pathophysiological mechanisms.

A third proposed mechanism for encephalitis as a complication of COVID-19 is molecular mimicry [1] . In response to infection with the SARS-CoV-2 virus, there is an expansion of host antibodies and lymphocytes. Although these immune molecules are supposed to be specific for SARS-CoV-2 viral antigens, some of them are crossreactive and can attack self-antigens [1] . When cells in the vascular endothelium and brain parenchyma are affected, diffuse damage to CNS results, which may cause the development of encephalitis [1] .

Notably, we found that the most common form of encephalitis in COVID-19 is autoimmune encephalitis [9, 21, 24, 30, 33] . There have also been reports of acute haemorrhagic necrotising encephalopathy [48] and Guillain-Barré syndrome [49] 

This systematic review and meta-analysis evaluated the epidemiology, clinical course, and outcomes of patients who suffered from encephalitis as a complication of COVID-19. Although the incidence of encephalitis in the general population of hospitalised COVID-19

patients was low at 0.215%, the mortality rate of patients who suffered from encephalitis as a complication of COVID-19 was high at 13.4%. Severely ill COVID-19 patients were much more likely to suffer from encephalitis as a complication. Further research through collaborative international registries would help to comprehensively decipher the pathophysiology and prognosis of encephalitis in COVID-19, improving the effectiveness of care.

We thank Toh Kim Kee for her assistance in designing the initial search strategy.

The authors declare no financial or other conflicts of interest. 

Research ethics approval was not applicable, as this submission did not involve human participants. All information was obtained from publicly available, published articles.

The views expressed in this article are entirely our own and not an official position of our institutions.

The data that support the findings of this study are openly available in PubMed. Additionally, the data that support the findings of this study are available from the corresponding author upon reasonable request.

https://orcid.org/0000-0001-5989-1424

Keng Siang Lee https://orcid.org/0000-0003-2308-0579

Neurological involvement in SARS-CoV-2 infection: a clinical systematic review

Stroke as a neurological complication of COVID-19: a systematic review and metaanalysis of incidence, outcomes and predictors

Early release-encephalopathy and encephalitis associated with cerebrospinal fluid cytokine alterations and coronavirus disease

Guillain Barre syndrome associated with COVID-19 infection: a case report

COVID-19-associated acute transverse myelitis: a rare entity

Neurological complications in critical patients with COVID-19

Immune-mediated neurological syndromes in SARS-CoV-2-infected patients

Intensive care for seriously ill patients affected by novel coronavirus sars-CoV-2: experience of the Crema Hospital, Italy

Plasmapheresis treatment in COVID-19-related autoimmune meningoencephalitis: case series

Encephalopathy in patients with COVID-19: a review

Meningoencephalitis associated with COVID-19: a systematic review

Encephalitic syndrome and anosmia in COVID-19: do these clinical presentations really reflect SARS-CoV-2 neurotropism? A theory based on the review of 25 COVID-19 cases

COVID-19-associated encephalitis: systematic review of case reports findings on cytokineimmune-mediated inflammation as an Underlying Mechanism

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

The ICD-10 classification of mental and behavioural disorders clinical: Descriptions and Diagnostic Guidelines

Extracorporeal membrane oxygenation in pregnant and postpartum women: a systematic review and meta-regression analysis

The methodological quality assessment tools for preclinical and clinical studies, systematic review and meta-analysis, and clinical practice guideline: a systematic review

Metaprop: a Stata command to perform meta-analysis of binomial data

Cochrane Handbook for Systematic Reviews of Interventions

A Language and Environment for Statistical Computing

Severe COVID-19-related encephalitis can respond to immunotherapy

Delirium and encephalopathy in severe COVID-19: a cohort analysis of ICU patients

Frequency of neurological presentations of coronavirus disease in patients presenting to a tertiary care hospital during the 2019 coronavirus disease pandemic

Imaging features of acute encephalopathy in patients with COVID-19: a case series

Neurology of COVID-19 in Singapore

Neurologic and neuroimaging findings in patients with COVID-19: a retrospective multicenter study

Frequent neurologic manifestations and encephalopathy-associated morbidity in Covid-19 patients

Assessment of neurological manifestations in hospitalized patients with COVID-19

Frequency of five unusual presentations in patients with COVID-19: results of the UMC-19-S1

The emerging spectrum of COVID-19 neurology: clinical, radiological and laboratory findings

COVID-19 impact on consecutive neurological patients admitted to the emergency department

The clinical spectrum of encephalitis in COVID-19 disease: the ENCOVID multicentre study

Inpatient neurology consultations during the onset of the SARS-CoV-2 New York City pandemic: a single center case series

Neurologic manifestations in 1760 COVID-19 patients admitted to Papa Giovanni XXIII Hospital

Neurologic manifestations in hospitalized patients with COVID-19: The ALBACOVID registry

Acute encephalopathy is associated with worse outcomes in COVID-19 patients

Encephalopathy in COVID-19 patients; viral, parainfectious, or both? Eneurologicalsci

Neurological and neuropsychiatric complications of COVID-19 in 153 patients: a UK-wide surveillance study

Real estimates of mortality following COVID-19 infection

Infections in the elderly critically-ill patients

Acute disseminated encephalomyelitis (ADEM) associated with COVID-19

COVID-19-associated acute disseminated encephalomyelitis: a case report

Post-infectious encephalitis in adults: diagnosis and management

Neuroimaging in encephalitis: analysis of imaging findings and interobserver agreement

COVID-19 and the brain: acute encephalitis as a clinical manifestation

SARS-CoV-2 and the nervous system: from clinical features to molecular mechanisms

Lifting the mask on neurological manifestations of COVID-19

SARS-CoV-2-associated acute hemorrhagic, necrotizing encephalitis (AHNE) presenting with cognitive impairment in a 44-year-old woman without comorbidities: a case report

A brief review of the neurological manifestations of the coronavirus disease

Additional supporting information may be found online in the Supporting Information section

Encephalitis as a neurological complication of COVID-19: A systematic review and meta-analysis of incidence, outcomes, and predictors